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Spending Health Care Dollars Wisely: 
Can Cost-Effectiveness Analysis Help? 
 
One question that is rarely asked, at least in polite company, is whether 
we’re getting the most health improvement possible for our money. In 
other words, are all the things that we do in medicine really worth it? 
That is where cost-effectiveness comes in. As a nation, we have been 
unwilling, at least publicly, to look explicitly at the value, in terms of 
improved health outcome, that we get for our health care dollars. With 
advances in medical technology putting unsustainable pressure on 
health care costs, our historical reluctance to measure value for health 
care may have to change. 
I start this brief by describing cost-effectiveness analysis as a method of 
determining the value, measured in Quality-Adjusted Life Years, of 
medical technologies as they are applied to treat, diagnose, or prevent 
various conditions. Based on this information, I then argue that some 
highly beneficial, low-cost procedures are significantly underutilized, 
and that other medical technologies may be overutilized based on the 
amount of health benefit they yield in relation to their cost. Next, I give 
examples from current research, my own and that of colleagues, 
illustrating how cost-effectiveness analysis can be used to guide the use 
of new diagnostic testing technologies (such as DNA or RNA typing of 
infectious agents or identification of genomic or proteinomic markers 
in cancer patients).  
Measuring Value for Health Care Dollars 
In last year’s Lourie Lecture, David Cutler, my colleague from Harvard 
University, argued that health care is good value on average. He asked 
the question, “Are the benefits of health care worth what we pay for 
it?” and his answer was generally “Yes, the benefits of health care are 
worth what we pay for it.” But that is not the same thing as saying that 
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all health care is good value. I submit that some health care is better 
value than the average and some health care is worse. Even though the 
average may be acceptable, there are some medical practices that are 
not worth the money we pay for them. Cost-effectiveness analysis is a 
method of determining the value of health care treatment. 
Dollars 
By money we mean the net resources consumed in providing the 
intervention, measured in dollars. This is relatively easy to determine, 
although not as easy as you might think. For now let’s just pretend that 
it’s relatively easy to measure the resources consumed in providing a 
health care intervention: the cost of the hospitalization, the physicians, 
the devices, the drugs, and all the rest of it. That’s the money part. 
Quality-Adjusted Life Years (QALYs) 
Value in health care, I submit, is best measured in terms of 
improvements in health outcomes, which may be increases in life 
expectancy or improvements in the quality of life. First, we assign 
relative weights to different qualities of life, ranging from perfectly 
healthy, at the top of the scale, or 1, to dead, at the bottom of the scale, 
or 0. Between those extremes are various levels of health, ranging from 
maybe having a little cold, which could be a .99, to having a very 
serious disability, such as after a stroke or possibly the end stages of 
cancer. 
Where do these weights come from? They derive from what people say 
they want. For example: How much relative value do people place on 
having relief from chest pain relative to having relief from fever or 
upper GI symptoms? We survey people in the community and ask them 
what their preferences are for various health conditions; this is integral 
in measuring health improvement. Then we take these weights that 
people assign to being in various states of health, multiply them by 
their durations, add them up, and we get a number of quality-adjusted 
life years (QALYs). See, for example, Bell et al. 2001. 
Measuring Quality-Adjusted Life Years for an Individual 
Figure 1 is a schematic of how one would measure the number of 
quality-adjusted life years lived by an individual who might be a 
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candidate for a treatment for asymptomatic coronary artery disease, 
such as a statin drug. Suppose this patient receives an initial treatment, 
is asymptomatic for some period of time, and then has a setback, starts 
experiencing chest pain, angina, for some period of time. This angina is 
certainly worse than being perfectly healthy. So the height of that bar is 
lower than the 1.0 for the asymptomatic period of time. After some 
time with angina, the patient undergoes surgery, recovers pretty well, 
but still has some minor limitations after the surgery. Eventually the 
patient suffers a major heart attack, then after a few years of being 
bedridden, dies. What is the number of quality-adjusted life years? It is 
essentially the total area underneath these bars. Our measure of health 
improvement, then, is an integrated measure of length and quality of 
life.  
Figure 1. Quality-Adjusted Life Years: Heart Attack Example 
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Measuring Value for Money 
Now how do we measure the value for money from a medical 
technology? How can a medical technology or clinical intervention 
affect costs and health outcomes? First, it can either increase or 
decrease cost. What do I mean by “decrease cost”? Some technologies 
may actually save money down the line, which is more than enough to 
offset the cost that you have to pay for it. The conventional wisdom is 
that prevention often falls into this cost-saving category, but it turns out 
that not all prevention is cost-saving. In fact, most prevention really is 
no more likely to be cost-saving than treatment. It could happen that a 
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treatment is cost-saving, and if it happens that a treatment is cost-
saving and also provides an improved health benefit, an improved 
health benefit in terms of longevity or quality of life or both, then the 
answer is “Yes, we want this technology.” We don’t even have to ask 
the question of value for money because it not only provides health 
improvement but also saves money. This situation is represented by the 
upper right-hand box in Figure 2.   
Figure 2. Cost-Consequence Space 
 Incremental Cost 
 + - 
+ ? Yes 
Inc
re
me
nta
l H
ea
lth
 E
ffe
ct 
- No ? 
 
The lower left-hand box in this table is equally clear; it costs money 
and it harms health outcome. We don’t want those. The problem, the 
battleground where we can’t afford to do everything for everyone, is 
located in the boxes with the question marks, and particularly the one in 
the upper left-hand corner. This is where most of health care is: it costs 
money and it provides a benefit. How can we evaluate these kinds of 
medical technologies? 
The Cost-Effectiveness Ratio: QALYs per $1 Million 
One measure is literally value for money. How many quality-adjusted 
life years does this technology buy for each dollar we spend on it?  
Net gain in health outcome (QALY) 
Net increase in health care cost ($) = Value for money 
It is the ratio of the quality-adjusted life years gained, the gain in health 
outcome, relative to the increase in health care costs. This is what I 
mean by value for money. 
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With that methodology it’s possible to make comparisons across 
medical interventions, in terms of how much health improvement you 
get for every dollar spent on the technology. 
Table 1. How Much Health Improvement (Quality-Adjusted Life Years) 
Can One Million Dollars Buy? 
Beta-blockade post myocardial infarction (MI), high risk >200 
Statin therapy, prior heart disease 100-200 
Beta blockade post MI, low risk 
Antihypertensive treatment, diastolic blood pressure (DBP)>105 
Cervical cancer screening every 4 years 
Screening sigmoidoscopy every 5 years 
Combination antiretroviral therapy for HIV 
50-100 
tPA (vs. streptokinase) for heart attack 
Coronary angiography and revascularization post MI, high risk 
Antihypertensive treatment, DBP 95-104 
20-50 
Dialysis for end-stage renal disease 
Statin therapy, low density lipoprotein (LDL)>190, high risk 10-20 
Coronary angiography post MI, low risk 
Statin therapy, LDL 160-190 or >190 and low risk 
Cervical cancer screening every year (vs. 2 years) 
<10 
Sources:Goldman et al. (1991), Prosser et al. (2000), Edelson et al. (1990), Frazier et al. 
(2000), Freedberg et al. (2001), Winkelmayer et al. (2002), Kuntz et al. (1996), Kim et al. 
(2002), Chapman et al. (2000). 
 
Table 1 lists various medical procedures. The numbers on the right side 
tell you how many quality-adjusted life years, on average, this medical 
technology will buy for every $1 million spent on it. At the top of this 
particular list is beta blockade—beta blocker drugs used after 
myocardial infarction—for patients who are at high risk for subsequent 
cardiac death. This is a very cost-effective intervention; more than 200 
quality-adjusted life years are gained for every $1 million spent. 
The “Gold Standard” of Twenty QALYs per $1 Million: Treatment 
of End-Stage Renal Disease 
The procedure highlighted near the bottom—dialysis for end-stage 
renal disease—which is in the category of 10 to 20 quality-adjusted life 
years gained per $1 million, is an interesting one. In 1972 Congress 
passed the End-Stage Renal Disease (ESRD) Amendment to Public 
Law 92-603, which expanded Medicare coverage of persons under age 
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65 who are disabled to include those with chronic renal failure, thus 
creating the only virtually universal health coverage program in the 
United States based solely on a disease. The best treatment for chronic 
renal failure is a kidney transplant; however, if a transplant isn’t 
available, these Medicare beneficiaries are entitled to dialysis. One of 
the earliest published cost-effectiveness analyses (Klarman et al. 1968) 
estimated that dialysis cost roughly $50,000 per year of life gained, or 
20 QALYs per $1 million. Surprisingly, that ratio, $50,000 per year of 
life gained, has had tremendous durability for patients on dialysis. Even 
as the cost of dialysis went up, the benefits also went up as 
immunosuppressant drugs were introduced and proved effective 
(Winkelmayer et al. 2002). This benchmark of 20 QALYs per $1 
million is frequently used as a benchmark for society’s willingness to 
pay for another life-year—although lower thresholds such as 10 
QALYs per $1 million have also been proposed (Cutler and Richardson 
1998). Presumably we ought to be willing to pay for everything above 
it on the list as well. Indeed, there are several interventions above it on 
the list: 
• Beta blockade post-MI is more cost-effective than dialysis, not only 
for high-risk patients but even for some low-risk patients.  
• On the other hand, coronary angiography after a heart attack, with 
the purpose of identifying patients who can benefit from coronary 
revascularization, either surgery or angioplasty or stent implants, can 
buy QALYs at about 20-50 per $1 million for high-risk patients, but for 
low-risk patients it falls near the bottom of the list at less than 10 
QALYs per $1 million. 
• Cervical cancer screening every four years is a very cost-effective 
thing to do. It is known to be beneficial and it is good value for money, 
50-100 QALYs gained per $1 million. But doing a pap smear every 
year instead of every 2 years gains fewer than 10, maybe a lot fewer 
than 10, QALYs per $1 million. 
These examples show that it is not really correct to say that a 
technology either is or is not cost-effective. Rather, it depends on how 
you are going to use it, which patients are going to get it, how often you 
are going to do it. It is the way you use technologies that determines 
how cost-effective they are. 
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Cost-Effectiveness Ratios: Dollars per QALY 
It is much more traditional to express these ratios upside-down, to 
measure dollars per QALY instead of measuring quality-adjusted life 
years per $1 million. The medical literature contains numerous studies 
that report cost-effectiveness ratios in terms of dollars per quality-
adjusted life year gained. These tend to run in the thousands up to the 
tens of thousands, even up into the hundreds of thousands of dollars per 
QALY. 
Reallocating Current Resources to Highly Cost-
Effective, Widely Applicable Technologies 
There is a wide range, maybe a factor of 100, between the most and the 
least cost-effective medical interventions that are widely used (Table 
1). And there is surprisingly little difference in the penetration of these 
technologies at the top of the list versus the penetration of these 
technologies at the bottom of the list into patient care. So there is a lot 
of room for reallocation of resources. We could improve our health 
outcomes as a community by taking some of the money that’s going 
into the technologies at the bottom and reallocating them to the 
technologies at the top, which are being underutilized. 
 
 
 
 
 
 
 
Figure 3 illustrates the total possible health improvement due to 
medical care, measured in quality-adjusted life years, for the amount 
we choose to spend. There is a little hash mark at 15% of the gross 
domestic product (GDP) to indicate our current level of health care 
Figure 3. Health-Maximizing Resource Allocation
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spending nationwide. The average health care gain per dollar is the 
slope of the diagonal line: this is the ratio of how much we get to how 
much we spend, and it is quite steep, representing good value of money 
on average. But look at the last percentage point or so of our health care 
dollars; they’re really not buying very much. We’re getting up to what 
Alain Enthoven (1980) calls “flat-of-the-curve medicine,” where there 
is little or no health improvement per dollar. 
Suppose that as a community we decide that we want our health care 
resources to be spent in the way that gives us the most possible health 
improvement as a community. What should we do? 
We should make sure that the interventions that give us the most value 
for money, the most health improvement per expenditure (QALYs per 
$) are done first, in the first part of the graph, where the slope is very 
steep and there is a lot of health improvement for a little bit of money. 
This includes beta blockers after MI and childhood immunizations; this 
is the really good-value-for-money medicine. We would want to make 
sure that everybody who needs those interventions gets them. So far, 
we’ve spent maybe 1/10% of GDP, and we’ve already gotten a fair 
amount of health improvement. Then we slide upward along the curve 
as we move down the list in Table 1 to the interventions that have 
slightly less value for money. We keep adding technologies until we hit 
our budget, 15% of the GDP. 
At this point, there is still more medical technology available that we’re 
not doing. If we’re only willing to spend 15% of the GDP, we’re going 
to have to forego some potential health improvement.  
But that isn’t how we allocate health care resources in this country. 
Instead, we tolerate situations where some highly cost-effective 
medical interventions don’t get done at all (Figure 4). Yes, we do the 
cost-effective interventions that we can’t not do, such as emergency 
appendectomies, but we skip over a few cost-effective interventions, 
maybe because they’re not very popular: colonoscopies, for example. 
People aren’t beating down their doctor’s doors to get colonoscopies. 
So we tolerate a situation where only a fraction of the population who 
could benefit from a colonoscopy to screen for colon cancer actually 
gets one. We skip over a few things until we reach less cost-effective 
technologies. Then, when we hit our 15% spending level, we have not 
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maximized the potential health improvement. We’re only getting part 
of the health improvement that we could get. 
 
 
 
 
 
 
If, starting at this point, we were to decide to add in all these 
underutilized but cost-effective medical interventions, we would end up 
spending even more. So instead we tolerate the fact that we’re not 
getting as much health improvement as we could for a country that 
spends 15% of the largest gross domestic product in the world on 
health care. We tolerate less than full utilization of good medical 
technologies to avoid spending even more than we are on health care.  
Underutilized Recommended Medical Technologies 
Table 2. Poor Adherence to Quality Indicators: 
De Facto Cost Containment? 
Type of Care 
Percent of 
Recommended Care 
Received 
 preventive 54.9 
 acute 53.5 
 chronic 56.1 
Mode of Care 
 medication 68.6 
 laboratory testing or imaging 61.7 
 surgery 56.9 
 counseling or education 18.3 
Overall 54.9 
Source: McGlynn et al. 2003, tables 3 and 4. 
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McGlynn and colleagues (2003) conducted a study on the percentage of 
recommended care that was received in different categories of care: on 
average only about 50 to 60 percent of recommended care is actually 
being delivered. What would it mean to increase that to 100 percent? It 
would mean more cost. But many of these underutilized services are 
cost-effective. They’re better value for money than a lot of what we’re 
doing. Examples of underutilized services include: 
• Flu vaccine for people over the age of 65. Studies have shown that 
this might even save more money than it costs, or at worst might cost 
$12,000 per QALY gained, which is a very good buy (Coffield 2001, 
Tables 1,2). Yet only 66 percent of Americans over 65 got flu vaccine 
in 2001 (CDC 2001, Table 7.1), and despite public education efforts 
only 74.5 percent of those on Medicare in 2003 received the vaccine 
(National Committee for Quality Assurance 2004, 36). This proportion 
was almost certainly lower in 2004 because of the nationwide shortage 
of flu vaccine. 
• Getting lipids managed after coronary heart disease events such 
as heart attacks. Statin drugs are very cost-effective for people who 
have already had a coronary attack and are at high risk of subsequent 
events. The cost per quality-adjusted life year is less than $10,000 for 
most risk groups, and even for lower risk women it is only about 
$40,000 per QALY (Prosser et al. 2000). And yet in 2003 only about 
65 percent of people with commercial insurance or Medicare who 
could benefit from these medications were getting them, and only 39 
percent of those on Medicaid (National Committee for Quality 
Assurance 2004, Appendix 1). 
• Colorectal cancer screening of people over the age of 50. Annual 
fecal occult blood testing (FOBT) is very cost-effective, less than 
$20,000 per QALY (Frazier et al. 2000). Even colonoscopies or 
sigmoidoscopies every 5 years cost less than $50,000 per QALY, 
which is the magic number for kidney dialysis. And yet as of 2003 only 
47.4 percent of commercially insured Americans and 49.5 percent of 
Medicare recipients received FOBT in the measurement year, 
sigmoidoscopy or double contrast barium enema within the last four 
years, or a colonoscopy within the last nine years (National Committee 
for Quality Assurance 2004, 32). 
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We tolerate this underutilization, and we restrict access to care, so that 
not only doesn’t everybody get the beneficial services, but we make it 
difficult for some people to get any services. Again, the net effect is 
that we end up spending a large amount of money but get less benefit 
than we could, and we find that there’s a lot that we are doing that is 
less beneficial per dollar than things that we are not doing. 
Evaluating New Medical Technology 
To evaluate a medical technology, we have to decide how it is going to 
be used, and then compare different uses. Most technologies that were 
worth developing in the first place are going to be effective, and even 
cost-effective, for some people some of the time. But there may be 
other people or other situations where they are much less cost-effective.  
Levels of Implementation 
We have to look at the cost-effectiveness, the ratio of the incremental 
cost to the incremental gain in QALY, for different levels of 
implementation or adoption of that technology, where the levels of 
implementation are defined by: 
• who gets it (the target population) 
• how we deliver it (modality), what particular form of the technology 
are we going to use, and  
• how often we are going to do it (frequency).  
Example: Cervical Cancer Screening 
These technology, modality, and frequency questions are nicely 
illustrated by a study that Sue Goldie and colleagues recently did on 
cervical cancer screening in clinical practice (Kim, Wright, and Goldie 
2002). 
The major cause of cervical cancer is human papillomaviruses (HPVs), 
a group of more than 100 known types of viruses (National Cancer 
Institute 2004). Some HPVs cause warts, or papillomas, which are 
benign, but others are associated with certain types of cancer. HPVs 
that are more likely to lead to the development of cancer are labeled 
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“high-risk,” as opposed to “low-risk” viruses that rarely lead to cancer. 
Even the majority of high-risk HPV infections go away on their own 
and do not cause cancer. 
Both high-risk and low-risk HPVs cause the growth of abnormal cells 
in the cervix, which can be detected by means of a pap smear. A pap 
smear removes a small amount of squamous, or epithelial, cells from 
the surface of the cervix. Among the pap smears performed annually in 
this country, about 2 million result in findings that are neither 
unequivocally normal nor cancerous, but are described as “atypical 
squamous cells of uncertain significance (ASC-US).” It’s been a matter 
of controversy what to do when the findings are equivocal, as in ASC-
US. The least costly strategy, which would probably be considered 
malpractice in some parts of this country, is to ignore those atypical 
findings, basically treat them as if they were normal pap smears. The 
standard of care, however, has been to repeat the pap smear until the 
results are unequivocal. 
Another approach to these atypical findings is a colposcopy, which may 
include freezing the abnormal cells or a cone biopsy, to determine with 
virtual certainty whether there is a lesion there or not.  
In 1999 the FDA approved a new technology, the Digene HPV DNA 
test, with which it is now possible to detect HPV virus in patients, and 
to distinguish whether it is a high-risk or a low-risk type. This DNA 
test is more expensive than a pap smear. Is it worth it? 
Kim, Wright, and Goldie (2002) performed a cost-effectiveness 
analysis of four management strategies for following up ASC-US 
findings: immediate colposcopy; HPV DNA testing, with a follow-up 
colposcopy if high-risk HPV types are detected; repeated pap smears; 
and reclassifying ASC-US as normal, that is, ignoring the equivocal 
result. They concluded that “reflex HPV DNA testing provides the 
same or greater life expectancy benefits and is more cost-effective than 
other management strategies for women diagnosed as having ASC-
US.” Table 3 summarizes their findings. 
These are incremental costs per life year gained, not quality-adjusted, 
but in cervical cancer the goal is basically to prevent fatal cancer. So 
cost per life-year pretty much captures what we’re interested in (except 
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that all these ratios would be slightly higher if they were expressed as 
costs per QALY, because the life years gained are in less than perfect 
health). Compared to doing nothing, doing a pap smear every 5 years 
and ignoring the atypical findings is a very cost-effective thing to do 
($7,100 per life year), but we can do better at only a little bit more cost. 
Instead of ignoring the atypical findings we could follow them up with 
an HPV test which, compared to doing nothing, would gain additional 
life-years at only about $12,000 apiece. The new pap smear technology, 
using liquid-based methods, is more expensive than the conventional 
pap smear, but it is also more effective, more sensitive and specific, and 
it turns out that it is good value to use the liquid-based technology. 
Table 3. Incremental Cost-Effectiveness of ASC-US 
Management Strategies and Screening Intervals 
Strategy 
Incremental 
Cost/LY 
Liquid-based, ignore ASC-US, 5 years $7,100 
Conventional, HPV, 5 years 12,100 
Liquid-based, HPV, 5 years 20,300 
Liquid-based, HPV, 3 years 59,600 
Liquid-based, HPV, 2 years 174,200 
Liquid-based, HPV, 1 year 794,000 
Liquid-based, colposcopy, 1 year 1,800,000 
Source: Kim, Wright, and Goldie 2002 
Intervals. We also find that these expensive technologies—the liquid-
based pap smear, and the human papilloma virus test—to work up 
atypical pap smears are very cost-effective as long as we test every five 
years. If we start thinking about doing it every 3 years, as is now 
widely recommended, the cost per life year gain is about $60,000, 
roughly equivalent to kidney dialysis. If we screen more often, say 
every 2 years or 1 year, the additional gain per dollar spent is very 
small. Or, as shown by these big numbers, the additional cost per life 
year gained is very high. What we also conclude is that these new 
technologies—liquid-based pap smears and the HPV test—are quite 
cost-effective, but that the annual pap smear is not. High tech wins out 
over low tech. 
Policy has changed, at least in part, because of this study. The 
American Cancer Society guideline committee that was set up to re-
examine cervical cancer screening in the United States in light of these 
new technologies concluded that the HPV test should be done to work 
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up atypical pap smear results, but that screening every 3 years, at least 
until there’s an abnormal or atypical finding, is sufficient (Saslow et al. 
2002). 
Example: Genotypic Antiretroviral Resistance Testing (GART) to 
Guide HIV Therapy 
Human Immunodeficiency Virus (HIV) is the virus that causes AIDS 
(Acquired Immune Deficiency Syndrome). Left untreated, HIV 
infection can damage a person’s immune system and progress to AIDS 
(AIDSinfo 2004). HIV is a retrovirus, a type of virus whose genetic 
information is contained in RNA rather than DNA. The U.S. 
Department of Health and Human Services (HHS) provides treatment 
guidelines that recommend a combination of three or more 
antiretroviral medications in a regimen called Highly Active 
Antiretroviral Therapy, or HAART. Using HAART has dramatically 
reduced HIV-related mortality and morbidity: a successful drug 
regimen reduces the amount of virus so that it becomes undetectable in 
a patient’s blood. However, the initial HAART can fail for several 
reasons: (1) these drugs may cause negative side effects, some of which 
may lead patients to discontinue treatment; (2) the HIV can mutate 
while a person is taking anti-HIV medication; or (3) drug-resistant 
strains may take over if the virus is not adequately suppressed by 
medication. Second and subsequent drug regimens are less effective in 
reducing a patient’s viral load, largely because of drug resistance. 
My colleagues and I recently did a cost-effectiveness study of a 
relatively new technology using genotyping for patients with HIV who 
have failed at least one antiretroviral treatment regimen (Weinstein et 
al. 2001). A Genotypic Antiretroviral Resistance Test, or GART, 
determines if the HIV in a particular patient has become resistant to the 
drugs the patient is currently taking or to the drugs that the patient’s 
physician is considering prescribing next. The test analyzes a sample of 
the virus from the patient’s blood to identify mutations that are 
associated with resistance to specific drugs. Thus it can help identify 
the drugs to which these patients are likely to respond, or to which their 
strain of HIV has not yet developed resistance, and increase the 
effectiveness of the next anti-HIV regimen. It is an effective 
technology. But it is also expensive, about $400 in 2001. 
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And GART is only modestly effective. It can increase the suppression 
rate of the virus in the second- and third-line regimens from 14% to 
20%, up to maybe 30%, but that is still not nearly as effective as the 
first-line regimens. So there is a lot of resistance to adopting this 
technology. 
In our study, we used a model, a so-called state transition decision 
analytic model: think of it as a “black box” of people with HIV 
infection. This model synthesizes evidence from clinical trials, from 
cohort studies such as the Multi-Center AIDS Cohort Study, efficacy of 
the treatments from clinical trials, and the efficacy of genotype testing 
from clinical trials. We put all these numbers into our model and out 
came our cost-effectiveness result, which is that, comparing a world 
without genotype testing to a world with genotype testing, patients with 
AIDS can gain about 2.5 months of QALY, and that the cost per 
quality-adjusted year of life gained is about $16,000. This is less than 
kidney dialysis, even less than a lot of those very high-value 
technologies in Table 1. It falls in the same range as treating high blood 
pressure for people with fairly high diastolic blood pressures, cervical 
cancer screening even every 4 years, or screening sigmoidoscopy for 
colon cancer every 5 years. 
Basically this study says that if it’s worth treating HIV with 
antiretroviral drugs, it’s worth doing the genotype test. To some, that 
was a surprising conclusion. It shows that expensive technology can be 
good value, but you have to look at how it’s being used, and whom it’s 
being used on. 
Example: HER-2 Testing and Trastuzumab Therapy for 
Metastatic Breast Cancer 
Breast cancer is a general term used to describe several different 
cancers that occur in the breast. One particularly aggressive breast 
cancer involves a genetic alteration that generates extra copies of the 
HER-2/neu gene, which sends protein signals to cells to grow and 
multiply normally. If the cell has extra HER-2/neu genes that produce 
too much signal protein, the growth signals are out of control, and 
breast cells reproduce abnormally and form a cancer (see 
http://www.vysis.com/Herceptin_35577.asp). Approximately 25% of 
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breast tumors are of this type. The HER-2 gene was linked with breast 
cancer in 1987.  
The drug trastuzumab, produced by Genentech Incorporated under the 
name Herceptin, is designed to block excess HER-2 protein. It is a 
monoclonal antibody that was approved by the FDA in 1998 to treat 
metastatic breast cancer in women whose tumors exhibit HER-2 protein 
overexpression (extra amounts of protein) or gene amplification (extra 
copies of the gene). Like many new drugs, it targets the tumor cells that 
overexpress the HER-2 protein. It is administered in combination with 
conventional chemotherapy, and randomized controlled trials show that 
trastuzumab improves the response rate of the tumors and the duration 
of the response, increases the time to progression of the cancer, and 
even increases overall survival. It is an effective drug, but it is 
expensive. Moreover, only 20% to 30% of women with breast cancer 
can actually benefit from it. 
There are two kinds of tests to identify the women who can benefit 
from Herceptin. 
• The immunohistochemistry (IHC) assay, which costs only $85 or 
so, measures HER-2 protein present on the surface of the tumor cells. 
The test results are expressed as 0, 1+, 2+ (weakly positive), and 3+ 
(strongly positive). A test result of 3+ indicates that the patient is HER-
2 positive, but results of 2+ or even 1+ may occur in women who are 
HER-2 positive.  
• The fluorescence in situ hybridization (FISH) test measures the 
HER-2/neu abnormality at the DNA level, that is, the number of HER-
2/neu genes in the cell nucleus, and it is significantly more accurate 
than the IHC test. But it costs $400. 
Using the less expensive IHC test alone, about 8% of women who 
could benefit from Herceptin and would be identified as candidates to 
benefit from Herceptin if they got the FISH test, are missed by the 
inexpensive test, because there are 8% false negatives. On the other 
hand, of the women who truly can not benefit, 1.7% would be 
identified as strongly positive and could get Herceptin unnecessarily 
and without benefit, based on the IHC test results alone. 
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Is it worth doing the $400 FISH test instead of the $85 IHC test to 
avoid missing the 8% of women who could benefit, and also to avoid 
unnecessarily giving Herceptin to the 1.7% of women who would be 
identified as positive or strongly positive (even more if you include the 
weakly positive results), but who really aren’t going to benefit? 
Our cost-effectiveness study (Elkin et al. 2004) analyzed five test-treat 
strategies based on results from clinical trials. The comparison strategy 
was no test and chemotherapy alone. This was compared to four 
strategies that involved various ways to identify and treat patients with 
Herceptin: (1) IHC test, Herceptin if the IHC result was 2+; (2) IHC 
test, Herceptin if 3+, confirm 2+ with FISH and give Herceptin if FISH 
results were positive; (3) FISH, Herceptin if FISH results were 
positive; and (4) no test, Herceptin to all patients. 
What we found was that doing anything is expensive per unit of 
benefit. This is because of the poor prognosis with metastatic breast 
cancer, and because the patients most likely to benefit from Herceptin 
have the poorest prognosis to begin with. Table 4 shows the costs per 
QALY gained. 
Table 4. Costs per QALY Gained for Test-Treat Strategies 
Strategy Dollars QALYs $/QALY 
No test, chemotherapy for all $43,300 1.28 - 
IHC test, FISH for 2+, 
Herceptin for FISH + 
$53,700 1.36 $125,000 
FISH, Herceptin for + $54,700 1.37 $145,000 
IHC Test, Herceptin for 2+ $57,500 1.36 Dominated 
No test, Herceptin for all $79,200 1.37 Dominated 
Notes: (a) The $/QALY is the ratio of the added cost to the added 
QALYs, comparing each strategy to the next less costly one. For 
example, the $/QALY for “IHC test, FISH for 2+, Herceptin for FISH + 
is calculated as ($53,700-$43,300)/(1.36-1.28). Dollar amounts are 
rounded. (b) Dominated means that the strategy is both less effective 
(fewer QALYs) and more costly than at least one of the other 
strategies. The last two strategies are dominated by the strategy 
“FISH, Herceptin for +”; their costs are higher but their QALYs are 
the same or lower. 
Source: Elkin et al. 2004. 
In contrast with the $15-20 thousand per QALY for AIDS drugs and 
resistance testing for AIDS treatment, and in contrast with $50,000 per 
QALY for kidney dialysis, these cost-effectiveness ratios are over 
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$100,000. In this context, the difference between using the $85 IHC 
test and the $400 FISH test is very small. You can conclude from this 
that if you are willing to spend the money to use anything at all, even to 
use Herceptin in the first place, you should probably be willing to use 
the expensive test to be sure that you get the drug to the right patients. 
Is it worth spending $125,000-$145,000 to gain one QALY for women 
with metastatic breast cancer? Well, it’s hard to say no to that question, 
but it does raise an interesting, and provocative, issue. A lot of women 
who should be getting screening mammograms aren’t getting them. 
Maybe if we made sure that all the women who could prevent this 
cancer by getting mammograms got them, we could do more good than 
by using these drugs. Of course that raises very difficult ethical issues. 
Do we want to say “no” to patients with cancer? 
The conclusions from this analysis are that if targeted treatment is 
worth doing, that is, if giving Herceptin is worth doing at all, then so is 
the more accurate and expensive test. But also that this whole set of 
interventions, both the testing and the treatment, have a relatively high 
cost-effectiveness ratio compared to other therapies and screening 
procedures for breast cancer. 
Who Cares About Cost-Effectiveness Analysis? 
Government Agencies 
You would think that in the United States the government would care. 
You would think that our representatives in Washington and in our 
state capitals would care that we’re getting the most health value for 
our money. To a certain extent they do care, but publicly our 
governments have been reluctant to embrace cost-effectiveness analysis 
(Neumann 2004).  
The Centers for Disease Control has taken a leadership position in 
using cost-effectiveness analysis in formulating guidelines for 
vaccination and screening programs, but those are basically 
recommendations.  
You would think that Medicare and the Medicaid agencies in the states 
would be using cost-effectiveness analysis, but they have pretty much 
avoided it like the plague. For political reasons Medicare has never 
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used cost-effectiveness analysis, at least openly or officially, and 
Medicaid agencies have only recently begun to look at it. In fact, as 
soon as our paper about the cost-effectiveness of genotype resistance 
testing in HIV was published in the Annals of Internal Medicine, I got a 
call from somebody in the Florida Medicaid office: “We saw your 
paper. We’re trying to get through the state legislature a law that will 
allow reimbursement for genotype resistance testing. Can you advise us 
on how to evaluate it?” Because the legislature was interested and was 
willing to provide reimbursement on a trial basis, the state Medicaid 
agency was interested in evidence that it would be a good use of state 
funds. 
Virtually the rest of the developed, industrialized world is waist deep in 
cost-effectiveness analysis. In the United Kingdom, which admittedly 
has a very different health care system, they have set up an organization 
called the National Institute for Clinical Excellence, with the beautiful 
acronym NICE, which requires cost-effectiveness analyses of 
pharmaceuticals and other technologies prior to a recommendation 
from NICE to the National Health Service regarding reimbursement. 
This agency has really been a full employment act for my colleagues in 
the UK who are doing some wonderful work, both on methodology and 
application of cost-effectiveness analysis. The National Health Service 
has actually put some restrictions on reimbursement for new drugs and 
technologies on the strength of cost-effectiveness analysis. 
This is also true of other countries in Europe, in Australia, and in 
Canada.  The Australian government and the Ontario provincial 
government in Canada were the first to require that reimbursement 
under their drug benefit programs be guided, and are still guided in 
part, by cost-effectiveness analysis. It appears that the rest of the world 
is already paying attention to value for money. 
The United States, on the other hand, is doing end runs around the issue 
by using other mechanisms: restricting access, demanding higher 
standards of evidence for new technologies, tolerating underutilization, 
and so on. 
Here in this country we rely a lot on the private sector: private health 
care payers, managed care organizations, and insurers. Bernie Bloom 
recently surveyed the people who identified themselves as the users of 
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economic evaluation information in managed care organizations 
(Bloom 2004). Forty-two percent of them said that they used cost-
effectiveness analysis or cost-benefit analysis. There may be others 
who wouldn’t admit it, but some managed care organizations are 
beginning to dip their toes in the water. They simply have to. 
Distorted Incentives 
Hospitals 
Some hospitals are starting to use, or at least pay attention to, cost-
effectiveness analysis, but there are barriers. For a hospital, for 
example, costs can be offset by revenues, and sometimes the incentives 
get distorted a bit. 
Take, for example, the case of drug-eluting stents. Drug-eluting stents 
have been shown to reduce the incidence of repeat coronary 
revascularization procedures, compared to bare metal stents. These 
drugs, which flow through the arteries, prevent a restenosis of those 
arteries that would otherwise require either more angioplasty 
procedures, stents, or bypass operations. Drug-eluting stents are a 
beneficial procedure that prevent subsequent bypass operations and 
angioplasties, so they save money. But not for the hospital, because the 
hospital can get paid to do those coronary bypass operations and 
angioplasties, and so can the physicians and surgeons. As a result, from 
the hospital’s point of view it’s a losing proposition to prevent bypass 
operations and angioplasties. The incentives are distorted. Even though 
the costs are reduced, the net revenue, the net income to the hospital, is 
actually harmed. This is not the fault of the hospitals, but it’s the way 
we’ve set things up in this country. 
Insurers 
Insurers tend to have a short-time horizon. If they’re for-profit they 
have to satisfy their shareholders that they’ve got good earnings this 
year. Besides, since most of their members are going to leave them 
pretty soon, they don’t care much about cost savings five, ten, or 
twenty years down the line. They care about costs now, and many times 
the payment for those downstream procedures will be paid by 
somebody else, like Medicare. So why prevent osteoporosis if by the 
time the woman breaks her hip Medicare is responsible for her health 
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care? We have multiple payers in this country. For that reason no single 
payer has the incentive to capture all of the potential costs and savings. 
Government Agencies 
Even government doesn’t have all the incentives lined up. Agencies of 
the government are not the same as The Government. They each have 
their own annual budgets, and they erect tests of so-called budget 
neutrality, which means, “We’re not allowed to do anything new this 
year in our Medicaid organization unless it can be offset by some 
savings.” So nothing new that can possibly provide health 
improvement, maybe even very good value health improvement, will 
get done unless it is demonstrably cost-saving as well. 
And of course none of these decision makers consider patients’ or 
families’ time and out-of-pocket expenses, which are part of the cost of 
health care. 
Conclusion 
Medical specialty organizations have begun to at least refer to cost-
effectiveness analysis in support of practice guidelines. The most recent 
cholesterol guidelines cite cost-effectiveness analyses showing that it’s 
very cost-effective to give cholesterol-lowering drugs to people after a 
heart attack, and, as I mentioned, the latest cervical cancer guidelines 
recognize the value of human papilloma virus testing, and possibly less 
frequent screening intervals. 
Physicians are seeing a proliferation of cost-effectiveness analyses in 
the leading medical journals. In fact, the Annals of Internal Medicine,  
the journal of the American College of Physicians, has a special 
structured abstract form for people who write cost-effectiveness 
studies. Those of us who do those studies and publish in that journal 
gladly adhere to those guidelines. So at least some physicians are 
reading these studies. They’re going out there in the real world as 
opinion leaders, educators, and practitioners and beginning to make 
known that as physicians they have a responsibility to be gatekeepers—
informed, educated, sensitive to patient needs, but nonetheless 
gatekeepers. 
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We can’t do everything for everybody. We’ve got to make choices. But 
we’re in a position to do it in both a humane and knowledgeable way.  
Can cost-effectiveness analysis contain health care costs? Maybe it will 
help. Will cost-effectiveness analysis improve health? I say yes, but 
only if it is used. 
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